Real-world evidence from clinical practices is fundamental for understanding the efficacy and tolerability of medicinal products. Patients with renal cell cancer were studied to gain data not represented by analyses conducted on highly selected patients participating in clinical trials. Our goal was to retrospectively collect data from patients with advanced renal tumours treated with pazopanib (PZ) to investigate the efficacy, frequency of side effects, and searching for predictive markers. Eighty-one patients who had received PZ therapy as first-line treatment were retrospectively evaluated. Overall survival (OS), progression-free survival (PFS) were assessed as endpoints. Median PFS and OS were 11.8months (95% CI: 8.8 22.4); and 30.2months (95% CI: 20.3 41.7) respectively. Severe side effects were only encountered in 11 (14%) patients. The presence of liver metastasis shortened the median PFS (5.5 vs. 14.8months, p= 0.003). Median PFS for patients with or without side effects was 25.6 vs. 7.3months, respectively (p= 0.0001). Patients younger than 65years had a median OS of 41.7months vs. 25.2months for those over 65years of age (p= 0.008). According to our results absence of liver metastases, younger age (65years) and presence of side effects proved to be independent predictive markers of better PFS and OS.
展开▼
